River Rhine, Mainz

Mainz, Germany: We’re back for Day 2 highlights from the Association of Cancer Immunotherapy (CIMT) with a look at some insights emerging from some academic and industry talks, as well as gems emerging from the poster halls.

Much attention is focused on cancer immunotherapy clinical data, yet it’s also important to watch out for new developments.

These can take many different forms such as what are companies doing to meet those challenges with novel therapeutics, as well as understanding more detail about immune mechanisms, including evasion and escape as well as defining phenotypes based on different immune cell populations.

As we head into ASCO, let’s not forget that there’s some important learnings to be had elsewhere in the world before we get there…

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by